Biopharmaceutical products are pharmaceuticals that are derived from life forms, and they require a patent for exclusive manufacturing rights. These items are manufactured in a cleanroom ecosystem with set standards regarding airborne particles. These drugs can be nucleic acids, including deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and antisense oligonucleotides, and proteins, including antibodies. They are generally used for in vivo diagnostic and therapeutic purposes.
Biopharmaceuticals have proven effective in treating diseases such as neurological disorders, cancer, and infectious diseases. These products are useful in the management of several neurodegenerative disorders as these ailments require direct administration of a drug into the brain, which is not achievable with traditional medications. Moreover, the ongoing technological developments have been able to enhance the survival rate of patients suffering from life-threatening diseases like hepatitis and cancer. The World Health Organization (WHO) estimates that cancer accounts for around 9.6 million deaths each year, globally. Thus, the surging incidence of chronic disorders will augment the biopharmaceuticals market revenue.
Therefore, with the increasing prevalence of cancer and CVDs, the requirement for biopharmaceuticals will rise in the foreseeable future. Additionally, the development of innovative and effective products and a soaring number of patent approvals to such pharmaceuticals will promote their administration, globally.
